Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway

Session led by neurosurgeon Dr. Fraser Henderson and Hemostemix CEO Thomas Smeenk for the University of Florida's Department of Surgery, Division of Vascular Surgery & Endovascular Therapy (Gainesville)

Calgary, Alberta--(Newsfile Corp. - November 13, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) today announced key highlights from its November 12, 2025 Grand Rounds presentation (to the University of Florida (UF, Gainesville) vascular team. The session, titled "Angiogenic Cell Precursors (ACP-01): Regenerating Microcirculation in CLI, Cardiomyopathy and Angina," was delivered by Fraser Henderson Sr., MD (neurosurgeon) with opening remarks and policy/operations updates from Thomas Smeenk, President & CEO.

Cannot view this video? Visit:
https://www.youtube.com/watch?v=yXog6bDxpKg

Attendees included UF vascular faculty and trainees and external clinicians, among them David Alper, DPM (Boston) and Kristina Giles (MaineHealth; formerly the UF ACP-01 trial coordinator). The discussion focused on clinical outcomes, safety, Florida's treatment pathway (SB 1768), and operational readiness to accept patients.

Session Highlights

1) Safety Profile Across >498 Treated Patients

• ACP-01 is autologous (patient-derived) and harvested via simple blood draw.

• No cell-related complications reported across more than 498 treated patients; ~300 are in peer-reviewed publications.

• Noted events in historical programs: one MI-unrelated death in an ineligible subject with a prior silent MI; two tachyarrhythmias responsive to cardioversion.

Quote - Dr. Henderson: "The autologous nature and endothelial programming of ACP-01 distinguish it from pluripotent or broadly multipotent cell types. What we consistently see is a favorable safety profile paired with biologic specificity for new vessel growth and inflammation modulation."

2) Cardiovascular Efficacy Signals (Cardiomyopathy & Angina)

• Ischemic & Dilated Non-Ischemic Cardiomyopathy: Multiple cohorts demonstrated a ~5% absolute LVEF increase, translating to ~16-47% improvement in cardiac function depending on subtype; +126 m in 6-minute walk; improvements in NYHA class.

• Angina (historical VesCell™/ACP-01 studies): Significant gains in 6-minute walk, exercise capacity (METs), perfusion by SPECT-MIBI, and CCS angina class at 3-6 months.

"I would like to THANK Dr. Shah and his colleagues at the University of Florida for hosting our Grand Rounds and for welcoming the vascular, cardiology, and podiatry specialists we invited," said Thomas Smeenk, CEO of Hemostemix. The University of Florida was one of 11 Phase II clinical trial sites. Its team has seen ACP-01's results patient by patient.